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Conxi Lázaro,5 Ángel Raya,2,3,6,* and Eduard Serra1,*
1Hereditary Cancer Group, Germans Trias i Pujol Research Institute (IGTP)-PMPPC-CIBERONC, Can Ruti Campus, Badalona, Barcelona 08916, Spain
2Center of Regenerative Medicine in Barcelona (CMRB), Hospitalet de Llobregat, Barcelona 08098, Spain
3Center for Networked Biomedical Research on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Hospitalet de Llobregat, Barcelona 08098,
Spain
4Clinical Genetics andGenetic Counseling Program,Germans Trias i Pujol University Hospital (HUGTiP), Can Ruti Campus, Badalona, Barcelona 08916, Spain
5Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL-CIBERONC), L’Hospitalet de Llobregat, Barcelona 08098, Spain
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https://doi.org/10.1016/j.stemcr.2019.01.001SUMMARYNeurofibromatosis type 1 (NF1) is a tumor predisposition genetic disease caused by mutations in the NF1 tumor suppressor gene.
Plexiform neurofibromas (PNFs) are benign Schwann cell (SC) tumors of the peripheral nerve sheath that develop through NF1
inactivation and can progress toward a malignant soft tissue sarcoma. There is a lack of non-perishable model systems to investigate
PNF development. We reprogrammed PNF-derived NF1(/) cells, descendants from the tumor originating cell. These NF1(/)-
induced pluripotent stem cells (iPSCs) captured the genomic status of PNFs and were able to differentiate toward neural crest stem cells
and further to SCs. iPSC-derivedNF1(/) SCs exhibited a continuoushigh proliferation rate, poormyelination ability, and a tendency to
form3D spheres that expressed the samemarkers as their PNF-derived primary SC counterparts. They represent a valuablemodel to study
and treat PNFs. PNF-derived iPSC lines were banked for making them available.INTRODUCTION
Neurofibromatosis type 1 (NF1) is a tumor predisposition
genetic disease (VM & Riccardi, 1992) caused by the inher-
itance of a mutated copy of the NF1 gene, a negative regu-
lator of Ras (Ratner and Miller, 2015). The major disease
features involve the nervous system, the skin, and the
skeletal system. There is a great variability in the clinical
expressivity of the disease, but the development of
different tumors of the peripheral nervous system, such
as cutaneous neurofibromas (CNFs), plexiform neurofi-
bromas (PNFs) or, less frequently, malignant peripheral
nerve sheath tumors (MPNSTs), constitute one of the
hallmarks of the disease (Ferner, 2007).
PNFs are mainly developed in the context of NF1 and are
thought to be congenital. They are identified in around
50% of NF1 individuals if MRI is used (Mautner et al.,
2008). This tumor type constitutes a major source of
morbidity (Prada et al., 2012) and, in some cases, undergoes
malignant transformation (McCarron and Goldblum,
1998). Surgery is still the standard therapeutic option.
However, complete resection can cause important func-
tional deficiencies and sometimes can be unfeasible
because of the size or location of the tumor (Packer and
Rosser, 2002). Recently, the MEK inhibitor SelumetinibStem Cell Rep
This is an open access article under the Chas been used in children with inoperable PNFs showing
confirmed partial responses (Dombi et al., 2016).
Neurofibromas are composed of different cell types,
mainly Schwann cells (SCs) and endoneurial fibroblasts,
as well as perineurial cells and infiltrating immune cells,
all embedded in an abundant collagen-rich extracellular
matrix (Krone et al., 1983; Peltonen et al., 1988). PNFs arise
through a biallelic inactivation of the NF1 gene (Däschner
et al., 1997; Hirbe et al., 2015; Kluwe et al., 1999; Rasmus-
sen et al., 2000). Only neurofibroma-derived SCs bear this
NF1 inactivation (Kluwe et al., 1999; Li et al., 2016; Maert-
ens et al., 2006; Muir et al., 2001; Serra et al., 2000). Like
CNFs, different PNFs arising in the same individual bear
different somatic NF1 mutations (Pemov et al., 2017).
Also, like CNFs (Garcia-Linares et al., 2011), no recurrent
gross genomic alterations or recurrent point mutations
have been identified in PNFs besides the involvement of
chromosome 17 in the inactivation of the NF1 locus (Beert
et al., 2011; Carrió et al., 2018; Miller et al., 2009; Pemov
et al., 2017). PNF progression to malignancy often occurs
through the formation of a pre-malignant lesion termed
atypical neurofibroma, which involves the additional loss
of the CDKN2A/B locus (Beert et al., 2011; Higham et al.,
2018). It has been shown in one case (Hirbe et al., 2015)
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and their subsequent MPNST and metastasis, linking the
PNF and MPNST cell of origin.
Different models for PNFs have been developed, both
in vitro (primary cells, immortalized cells, 3D culture
models) and in vivo (genetically modified mouse models).
Primary SC cultures from PNFs have been established
(Wallace et al., 2000). However, these cultures are perish-
able after several passages, limiting their use for molecular
and cellular analyses that require large amounts of cells. To
overcome this problem, immortalized cell lines have been
generated (Li et al., 2016), but inextricably alter the biolog-
ical status of the cells. These cells have also been used to
generate 3D models (Kraniak et al., 2018) to better recapit-
ulate the natural PNF environment of SCs. In addition,
different genetically modified animal models using the
Cre/lox system to ablate NF1 in specific cell stages of the
neural crest stem cells (NCs, for simplicity)-SC axis during
development have been generated that develop PNFs
(reviewed in Buchstaller et al., 2012). Furthermore, Chen
et al. (2014) established a non-germline model of PNF,
consisting of the transplantation of Nf1-deficient embry-
onic dorsal root ganglia/nerve root neurosphere cells to
sciatic nerves of nude mice.
Another way of obtaining imperishable cell-based model
systems is the generation of induced pluripotent stem cells
(iPSCs) (Takahashi and Yamanaka, 2006). iPSCs have been
generated to model hereditary cancer syndromes (Papape-
trou, 2016), like Fanconi anemia (Raya et al., 2009). iPSCs
for NF1n have also been developed (Anastasaki et al.,
2015; Larribere et al., 2015; Wegscheid et al., 2018). How-
ever, as for most other cancer syndromes, NF1 iPSCs have
been generated from patient fibroblasts and not directly
from cells of the associated tumors.
iPSC technology has been used to reprogram cancer cells,
encountering different obstacles, such as their chromo-
somal and genomic composition or the necessity of remod-
eling their epigenetic state. Another limiting factor is the
cell type to be reprogrammed. These aspects make the effi-
ciency of generating iPSCs from cancer cells low (Kim and
Zaret, 2015). Despite the low efficiency, there are several ex-
amples of iPSCs generated from cancer cells (Pan et al.,
2017), mainly from established cancer cell lines (Bernhardt
et al., 2017) and much less common from primary tumors
(Kim et al., 2013; Kotini et al., 2017). However, the genera-
tion of iPSCs from benign tumors or pre-malignant lesions
has been less explored (Papapetrou, 2016). To generate a
non-perishable cell-based model system that recapitulates
the genetic content and tumorigenic properties of NF1
benign PNFs, we generated iPSCs directly fromPNF-derived
primary cells. These iPSCs were differentiated to NCs and
further to SCs. NF1(/) SCs obtained from PNF-derived
iPSCs were extensively characterized and compared with
primary NF1(/) SCs derived from primary tumors.412 Stem Cell Reports j Vol. 12 j 411–426 j February 12, 2019RESULTS
Generation of PNF-Derived iPSC Lines
We obtained five different PNFs (code-named 3PNF, 5PNF,
6PNF, 7PNF, and 13PNF) from five independent patients
diagnosed of NF1 according to standard diagnostic criteria
(DeBella et al., 2000). For most of them, histological infor-
mation is available (Carrió et al., 2018). PNFs are composed
of different cell types, mainly SCs and endoneurial fibro-
blasts. SCs within PNFs are the only cells bearing the two
NF1 alleles inactivated, one by a constitutional mutation
shared by all cells of the individual, and the other by a so-
matic mutation specific for each PNF. Our intention was to
create an imperishable cell-basedmodel resource by reprog-
ramming NF1(/) cells present in PNF descendants from
the cell originating them. In addition, we planned to
obtain NF1(+/) isogenic iPSCs from the same tumors.
We first determined theNF1 germlinemutation of each pa-
tient by next-generation sequencing panel analysis (Castel-
lanos et al., 2017) and also the NF1 somatic mutation of
each excised PNF (Table 1; Figure S1). NF1(/) iPSCs
were generated either from pure cultures of PNF-derived
NF1(/) SCs (Serra et al., 2000) or directly from a short
culture of PNF-dissociated cells. NF1(+/) iPSCs were ob-
tained by reprogramming either cultures of PNF-derived
NF1(+/) endoneurial fibroblasts, directly from PNF-disso-
ciated cells or from skin-derived fibroblast cultures of the
same patients (see Table S1 for details). Reprogramming
to pluripotency was induced by retrovirus- and/or Sendai
virus-mediated transduction (Ban et al., 2011; Takahashi
and Yamanaka, 2006) of the patient-derived cells. Table 1
summarizes information on patient (sex, age, and germline
mutation), tumor (diagnostic and NF1 somatic mutation),
and iPSC (name and banking information). Further reprog-
ramming information is summarized in Table S1.
Overall, we generated seven genetically different iPSC
lines from five independent NF1 patients. We were able
to isolate two independent NF1(/) iPSCs, bearing the
constitutional and somatic NF1 mutations, from five
distinct PNFs. From all five patients we obtained
NF1(+/) iPSCs bearing only the constitutional mutation.
Thus, from two different tumors, 3PNF and 5PNF, we
were able to generate isogenic iPSC lines bearing two
distinct NF1 genotypes: NF1(+/) and NF1(/) (Table 1).Characterization of PNF-Derived iPSC Lines
After confirming the NF1 genetic status, selected iPSC
clones representing each patient and NF1 genotype were
further expanded and characterized. Figure 1 illustrates
the characterization of the isogenic iPSC lines derived
from 3PNF and 5PNF; the characterization of the remain-
ing banked iPSC lines is shown in Figure S2. We selected
Table 1. Patient, Tumor, and iPSC Line Information













3 XX 8 c.3943C > T;
p.Gln1315*






5 XY 10 intragenic deletion
(E16-35)
5PNF PNF with diffuse
extraneural invasion
LOH (3.8Mb del) 5PNFiPS(NF1+/) 5PNF_TDiPSsv_PM
5PNFiPS(NF1/) 5PNF_TDiPSsv_MM
6 XX 33 c.2946delT;
p.Leu983*





7 XX 66 c.2033dupC;
p.Ile679Aspfs*21
7PNF PNF with diffuse
extraneural invasion
LOH (1.4Mb del) 7PNFiPS(NF1+/) 7PNF_TDiPSrv_PM
13 XY 14 c.1318C > T;
p.Arg440*





LOH, loss of heterozygosity; HR, homologous recombination. The link below will take you to the Spanish National Stem Cell Bank-Institute of Health Carlos
III, where the iPSC lines have been deposited to be able to be distributed. http://www.eng.isciii.es/ISCIII/es/contenidos/fd-el-instituto/fd-organizacion/
fd-estructura-directiva/fd-subdireccion-general-investigacion-terapia-celular-medicina-regenerativa/fd-centros-unidades/fd-banco-nacional-lineas-
celulares/fd-lineas-celulares-disponibles/lineas-de-celulas-iPS.shtml.clones that displayed a compact embryonic stem cell-like
morphology, were positive for alkaline phosphatase stain-
ing, and expressed high levels of pluripotency-associated
transcription factors and surface markers (Figures 1A
and 1B). Moreover, selected clones showed pluripotent dif-
ferentiation ability in vitro and in vivo (teratoma formation),
demethylation of POU5F1 andNANOG promoters, and kar-
yotype stability after more than 15 passages (Figures 1C–1F
and S2). It is worth noting that 5PNFiPS(/) carried a
chromosomal translocation (karyotype: 46,XYt(17; 22)
(q11.2; q13.3)) also present in the parental reprogrammed
SCs, as the cause of NF1 somatic inactivation (Figure S2G).
Finally, we confirmed by PCR-based DNA fingerprinting
analysis that the iPSC lines generated genetically matched
their parental tumors (Table S2). As expected, the levels of
neurofibromin were reduced in NF1(+/) iPSCs compared
with control NF1(+/+) pluripotent cells, and were absent
in NF1(/) iPSCs (Figure 2G). Altogether, these data
demonstrated that we successfully generated iPSCs from
PNF-derived NF1(+/) and NF1(/) cells, and indicated
that reduced levels or even absence of neurofibromin did
not appear to compromise somatic cell reprogramming
to pluripotency, maintenance, or differentiation capacity
of iPSCs.
PNF-Derived NF1(/) iPSCs Exhibit a Higher
Proliferation Rate Than Control Pluripotent Cells
It has been shown that NF1-deficient cells exhibit a higher
proliferation rate than their cellular counterparts carrying
one or two wild-type copies of the NF1 gene (Kim et al.,
1995, 1997; Rosenbaum et al., 1995). Consistent withthis, we noticed that cultures of NF1(/) 3PNFiPS and
5PNFiPS needed to be split more frequently than control
iPSCs or human embryonic stem cells (hESCs) maintained
in parallel. To quantify the effect of the NF1 status on iPSC
proliferation rate, we used a flow cytometry-based Click-iT
EdU assay. We compared PNF-derived NF1(+/) or (/)
iPSC lines with control NF1(+/+) pluripotent stem cells
(PSCs). Control cells included iPSCs from skin fibroblasts
of a healthy donor (FiPS cell line) and embryonic stem cells
(ES4 cell line). On average,NF1(/) 3PNFiPS and 5PNFiPS
cell lines exhibited a 10%–15% increase in cell proliferation
rate compared with control PSCs (Figure 2H). NF1(/)
iPSCs also exhibited a higher proliferation rate than
NF1(+/) iPSCs (p < 0.05). These results indicate that cell
proliferation rate in PSCs, as is the case for somatic cells,
is influenced by neurofibromin activity.
PNF-Derived iPSCs Capture the Genomic Status of
Their Cell of Origin
We extensively characterized the genomic content of the
different iPSC lines generated fromPNFs.We performed cy-
togenetic karyotyping, exome sequencing, and molecular
karyotyping by SNP array analysis comparing tumors,
NF1(/) SC and NF1(+/) fibroblast cultures and iPSCs.
All samples were 2n according to the cytogenetic and mo-
lecular karyotypes (Figures 1F, 2A, S2, and S3). As previously
observed in CNFs (Garcia-Linares et al., 2011), the only
genomic alterations present resulted from the somatic
inactivation of the NF1 gene, in some cases affecting the
structure of chromosome 17q (Figures 2 and S3) (Carrió
et al., 2018). Gross somatic mutations affecting the NF1Stem Cell Reports j Vol. 12 j 411–426 j February 12, 2019 413
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gene were found in four of the tumors and consisted
in either large deletions of 1.4 Mb (7PNF) and 3.8 Mb
(5PNF), both involving the NF1 and SUZ12 genes, or ho-
mologous recombination (3PNF and 13PNF) generating
loss of heterozygosity (LOH) in almost the entire 17q arm
(Figure 2B) and bringing the constitutional NF1 mutation
into homozygosity, as described previously (Serra et al.,
2001; Steinmann et al., 2009). Somatic NF1 inactivation
in 6PNF was due to a point mutation (Table 1; Figure S1).
The same somatic NF1 inactivation was shared by PNF
and its derived NF1(/) SC culture, but was not present
in fibroblast cultures or in NF1(+/) iPSCs (Figures 2 and
S3). We also performed exome sequencing to identify the
presence of small pathogenic variants. On average, we
identified the presence of ten additional point mutations
in thewhole exome of PNF-derived iPSCs thatwere not pre-
sent in PNFs or primary SC cultures (Figure 2C; Table S3).
The lownumber ofmutations is consistentwith the reprog-
ramming and clonal expansion of a cell already containing
thesemutations, whichwould not be detectable in the bulk
cell population of PNFs or primary SC cultures. None of the
identified somatic point mutations was recurrent among
the five PNFs (data not shown for 13PNF). These results
are in agreement with data from recent exome analysis of
PNFs and CNFs (Gosline et al., 2017; Pemov et al., 2017).
Neural Crest Differentiation of PNF-Derived iPSCs
We posit that PNF-derived iPSCs constitute a non-perish-
able cell-based experimental system that should facilitate
the identification of the PNF cell of origin as well as the
development of therapeutic strategies against these types
of tumors. Thus, we next set out to differentiate PNF-
derived iPSCs toward the NC-SC axis. To generate NCs,
we used a previously described differentiation protocol
that employs chemically defined medium to activate Wnt
signaling while inhibiting Activin/Nodal/transforming
growth factor b signaling (Lee et al., 2007; MenendezFigure 1. Characterization of PNF-Derived iPSC Lines
(A) Morphology and alkaline phosphatase staining of 3PNF and 5PNF
(B) Characterization of pluripotency markers. Representative images o
associated markers NANOG, OCT4, and SOX2 (in green), and TRA-1-81
(C) In vitro differentiation potential of 3PNF and 5PNF iPSC lines. Gene
ectoderm (TUJ1 in green and GFAP in red), endoderm (AFP in green a
Scale bars, 100 mm.
(D) Teratoma formation from 5PNF iPSC, showing their differentiation
green and FOXA2 in red) and mesoderm (SMA in green and GATA4 in
(E) Bisulphite sequencing showing demethylation of NANOG and POU
(F) Karyotype of 3PNF and 5PNF iPSC lines at passage 20.
(G) Western blot analysis showing the absence of neurofibromin in 3
(hESC) line ES4 and a control iPSC line generated from foreskin fibrob
(H) Proliferation capacity of 3PNF and 5PNF iPSC lines assessed by Click
represented in the graph. Bars represent means from three independeet al., 2013) (see Supplemental Experimental Procedures
for details).
Control PSCs, as well as all NF1(+/) and NF1(/) PNF-
derived iPSC lines tested, successfully differentiated toward
NC cells when applying this protocol. Approximately
12 days after NC induction, cells adopted a stellate
morphology typical of NCs (Figure 3A), which was main-
tained throughout the passages. To characterize the gener-
ated NCs we performed flow cytometry analysis using two
specific NC markers, p75 (NGFR) and HNK1 (Lee et al.,
2010), at early (7–10 days, passage 1) and late (>20 days,
passage 4–5) differentiation stages (Figure 3B). Although
both markers were heterogeneously expressed in early pas-
sages, NCs from both control and PNF-derived iPSCs ho-
mogeneously co-expressed high levels of p75 and HNK1
at later differentiation stages, indicating a clear NC iden-
tity. NCs cultured under these specific conditions could
be maintained as a stable, self-renewing population for
up to 20 passages without losing NC identity (see below),
enabling the freezing and cryopreservation of NC batches
for subsequent differentiation assays.
NC identity was further confirmed by immunofluores-
cence (Figure 3C) and qRT-PCR (Figure 3D) analyses of
the NC markers SOX10, p75, and AP2. qRT-PCR analyses
also showed that PSC-derived NCs did not express the plu-
ripotency-associated marker OCT4 (POU5F1), or the SC
lineage-specific marker S100b, present in PNF-derived
SCs (Figure 3D). Moreover, we also functionally tested
NC biological capacities such as migration and differentia-
tion potential. A scratch assay showed the ability of all
NCs (control and PNF derived) to start migrating already
at 6 h and to be able to close the scratch in less than
24 h (Figure S4A). Furthermore, PSC-derived NCs were
able to undergo further differentiation into NC-derived
cell types, such as peripheral neurons and melanocytes
(Figure S4B), confirming their NC multi-lineage differenti-
ation ability.iPSC colonies. Scale bars, 100 mm.
f 3PNF and 5PNF iPSC colonies stained positive for the pluripotency-
, SSEA3, and SSEA4 (in red). Scale bars, 100 mm.
ration of cell derivatives of the three primary germ layers including
nd FOXA2 in red) and mesoderm (SMA in green and GATA4 in red).
toward ectoderm (TUJ1 in green and GFAP in red), endoderm (AFP in
red). Scale bars, 100 mm.
5F1 promoters in the 3PNF and 5PNF iPSC lines.
PNFiPS(/) and 5PNFiPS(/). The human embryonic stem cell
lasts (FiPS), both NF1(+/+), were used as control cell lines.
-iT EdU Flow Cytometry Assay. Double-positive cells (in S phase) are
nt experiments.*p < 0.05 (unpaired t tests).
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SC Differentiation of PNF-Derived NCs
We then set up an SC differentiation protocol starting from
the established NCs. We differentiated NCs from control
FiPS and PNF-derived iPSC lines into SCs (Figure 4A) (see
Supplemental Experimental Procedures). The differentia-
tion process was monitored by immunocytochemistry
and qRT-PCR analysis of various markers of the NC-SC
lineage at different time points (7, 14, and 30 days).
After 7 days under SC differentiation conditions, NCs
from NF1(+/+) control FiPS already changed morphology,
becoming more elongated. This phenotype progressed
over time until reaching the typical bipolar spindle-like
morphology of SCs between 14 and 30 days of differentia-
tion (Figure 4B). SC markers such as p75 and S100b were
expressed homogenously in the culture throughout the
whole differentiation process (Figure 4B). qRT-PCR analysis
confirmed expression of NC-SC lineage-specific markers
throughout the differentiation process (Figure 4D). NGFR
and SOX10, two key regulators of NC formation and SC
fate determination, persisted during the entire differentia-
tion process. Expression of SC precursor markers such as
CDH19, ITG4A, and MPZ had a remarkable increase after
7 days of differentiation. GAP43was also highly expressed.
SC markers such as PLP, PMP22, and S100b were already
detected after 1 week of differentiation and reached
maximum expression by day 30. EGR2 (KROX20), a master
regulator for myelinating SC was detected already in NCs
and had a peak at 30 days of differentiation, as reported
previously (Jessen and Mirsky, 2005; Reiprich et al., 2010)
(Figure 4D).
At 7 days of differentiation NF1(/) NCs resembled
control NF1(+/+) cells, both morphologically and accord-
ing to SC marker expression (p75 and S100b) (Figure 4C).
After 14 days of differentiation, NF1(/) cells already
acquired the slender, elongated morphology of SCs.
However, whereas control NF1(+/+) cultures progressively
stopped proliferation,maintaining a homogeneous expres-
sion of SC markers, NF1(/) cells continued to exhibit a
high proliferation capacity and heterogeneously expressed
some of themarkers, such as S100b (Figure 4C). This altered
differentiation process of NF1(/) SCs was also observedFigure 2. Genomic Characterization of PNFs, Primary Cells, and G
(A) B allele frequency (BAF) data from SNP array analysis characterizin
fibroblasts; PNF-derived Schwann cells; 3PNFiPS(+/) and 3PNFiPS(
signal around 0.5. A blue shaded region indicates somatic copy neut
(B) A detailed view of BAF for chromosome 17. Somatic NF1 inactivatio
and the reduction to homozygosity for the constitutional NF1 mutat
Schwann cells and in 3PNFiPS(/). Fibroblast primary culture (3PNF
the presence of ‘‘contaminating’’ tumor SCs.
(C) Summary of somatic exonic variants identified by exome sequen
horizontal line of the same color covering all chromosomes. Color dot
(orange), in-frame deletion (purple), and non-sense (red). Position oby qRT-PCR analysis (Figure 4E). While markers of
the NC-SC lineage were expressed in differentiation
NF1(/) SC cultures, those markers related to SC matura-
tion were not maintained through the differentiation pro-
cess compared with control NF1(+/+).
NF1(/) Differentiating SCs Exhibited a Continuous
High Proliferation Rate and a Lack of Myelination
Capacity
NF1(/) differentiating SCs proliferated so much during
differentiation experiments that cultures were generated
with a high cell density and a natural tendency to form
sphere-like structures visible to the naked eye. Spheres
grew either attached to the plate surface or as free-floating
cultures resembling 3D spheroids (Figures 5A and 5B). We
quantified the proliferation capacity of differentiating SCs
by Ki-67 immunostaining (Figure 5C), confirming a statis-
tically significant higher proliferation rate in NF1(/)
cells, both at 7 and at 30 days of SC differentiation,
compared with control NF1(+/+) and NF1(+/) cell lines
(Figure 5D).
In addition to the proliferation rate of differentiating
SCs, we also tested their ability to myelinate axons.
NF1(+/+) FiPS-derived SCs, co-cultured with rat dorsal
root ganglion (DRG) neurons in the presence of myelinat-
ing medium, were capable of associating and myelinating
peripheral neuron axons, as demonstrated by the co-local-
ization of S100b/myelin protein zero (MPZ)-positive cells
with neuron-specific tubulin (TUJ1)-positive axons (Fig-
ure 5E). We identified fragments of myelinated axons
longer than 400 mm in three independent experiments
(Figure S5). These functional assays confirmed the myeli-
nating capacity of FiPS-derived SCs and validated the pro-
tocol used to differentiate NCs into SCs. However, when
we co-cultured NF1(/) iPSC-derived SCs with DRG neu-
rons, they kept proliferating during the assay and were not
able to properly associate and form myelinating axons,
neither cells growing in monolayer nor sphere-forming
cells, as happens in PNFs (Figure 5F). NF1(/) differenti-
ating SCs generated either spheres or wide lanes of orga-
nized cells. In addition, NF1(/) cells expressed theenerated iPSCs
g the genomic structure of five samples associated with 3PNF tumor;
/). The genome of all samples was mostly 2n, denoted by a BAF
ral (CN)-loss of heterozygosity (LOH).
n was produced by mitotic recombination generating CN-LOH in 17q
ion. LOH is observed in 3PNF and in 100% of cells in 3PNF-derived
fibroblasts) is an early passage and still exhibit a residual LOH due to
cing. All samples associated with a PNF are represented by wide
s indicate the type of genetic variant: missense (black), frameshift
f genes containing the variants is marked with vertical lines.
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Figure 3. PNF-Derived iPSCs Correctly Differentiate into NCs
(A) Schematic representation of the protocol used for differentiating iPSCs into NCs. Control (ES4 and FiPS) and PNF-derived
iPSCs were seeded on Matrigel and cultured in NC induction medium for 20 days (see Supplemental Experimental Procedures).
Representative bright-field images during the differentiation process over time (in days, D) are shown. PSC, pluripotent stem cell. Scale
bar, 50 mm.
(B) Flow cytometry analysis for p75 and Hnk1 before and after NC differentiation. The percentage of double p75 and Hnk1-positive cells is
shown inside the graph. P1, passage 1; P4-5, passages 4–5.
(legend continued on next page)
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neuronal marker TUJ1, complicating the analysis. Since
TUJ1 was not expressed by NF1(+/+) differentiating SCs
in the co-culture assay, we analyzed PNF-derived primary
SC cultures and found that they also expressed TUJ1
(Figure 5G).Sphere-Forming SCs from NF1(/) iPSCs
Recapitulate the Expression Pattern of Their PNF-
Derived Primary SC Counterparts
To have a better idea to which extent sphere-forming
NF1(/) differentiating SCs from PNF-derived iPSCs reca-
pitulated the expression of their primary PNF counterparts,
we compared the expression of SC markers in NF1(/)
spheres at 30 days of differentiation with the expression
of their parental PNF-derived primary SCs (Figure 6A).
In contrast to the heterogeneous expression of SC markers
(s100b) exhibited by differentiating SCs growing in
monolayer (Figure 4C), sphere-forming SCs homogeneous-
ly expressed all markers tested. When we analyzed the
expression of p75, s100b, SOX10, GAP43, and PLP by
immunofluorescence, the expression pattern of PNF-
derived SCs and sphere-forming SCs were strikingly similar
(Figure 6A).
Sphere-forming SCs bore the same genetic and genomic
content as their primary SC counterparts and recapitulated
both a high proliferation rate and the same expression
pattern in a homogeneous manner. Taking everything
together, NF1(/) iPSC-derived spheres represent a valu-
able experimental model to study PNF formation, and to
test potential therapeutic options in vitro (Figure 6B).DISCUSSION
There exists a lack of imperishable cell-based systems to
model benign tumor progression and assay therapeutic
strategies. PNFs are benign SC tumors of the peripheral ner-
vous system associated to NF1 that can progress toward a
malignant soft tissue sarcoma. We have generated
NF1(/) iPSC lines directly from PNFs, sharing the same
constitutional and somatic NF1 mutations as the cell
originating them. We also generated five independent
NF1(+/) iPSCs from five PNFs, two being isogenic to the
NF1(/) iPSC lines established. These cells have the ge-
netic and genomic content of their parental primary cells,
and can be differentiated toward NCs and further to SCs.(C) Immunocytochemistry analysis showing that both control (ES4 a
express p75 (green), AP2 (green), and SOX10 (red). DAPI was used to
(D) qRT-PCR expression analysis of pluripotent (POU5F1), NC (NGFR, SO
differentiated to NCs and PNF-derived SCs. qRT-PCR values are expres
three independent differentiation experiments.SCs derived from NF1(/) iPSCs exhibit a high prolifera-
tion rate, show poor ability to myelinate, and show a ten-
dency to form spheres in culture that resemble PNFs and
preserve the same expression marker profile of the NC-SC
axis as their parental NF1(/) primary SCs.
iPSC technology has been used to reprogram cancer cells,
encountering different obstacles, like the chromosomal
and genomic composition of cancer cells or the necessity
of remodeling their epigenetic state. The NF1(/) iPSCs
described here may have overcome these problems since
they have been generated from benign tumors. Reprogram-
ming technology has been previously used tomodel hered-
itary cancer syndromes (Papapetrou, 2016), NF1 among
them (Anastasaki et al., 2015; Larribere et al., 2015; Wegsc-
heid et al., 2018), but never from cells of the associated tu-
mors. PNFs have the potential to progress tomalignancy. In
this regard, we believe that these iPSCs could constitute an
excellent model for investigating tumor progression when
combined with existing DNA-editing tools (CRISPR-Cas9)
to better identify the genetic and epigenetic changes
required for malignant transformation.
Even though the relatively low number of samples com-
plicates drawing strong conclusions, we noticed that the ef-
ficiency of generating NF1(/) iPSC lines from PNFs (also
NF1(+/)) varied depending on the tumor and on the start-
ing cell type. Different factors could be involved, such as
the culture conditions used, the different reprogramming
efficiency of distinct cell types (reviewed in Ebrahimi,
2015) or the age of the PNF donor, although all these as-
pects would need to be further explored.
Whereas NF1(+/+) differentiating SCs progressively
stopped proliferation, maintained a homogeneous expres-
sion of SC markers, and had the capacity to myelinate
axons,NF1(/) cells continued exhibiting a high prolifer-
ation capacity and heterogeneously expressed S100b dur-
ing differentiation, and exhibit a poor ability to myelinate
axons. These results are consistent with the biological sta-
tus of SCs within PNFs. The exact mechanism and role of
the NF1 gene in relation to the altered SC differentiation
is an exciting topic for further research.
The PNF-resembling spheres generated by the high pro-
liferation capacity of differentiating SCs from PNF-derived
NF1(/) iPSCs constitute a very promising non-perish-
able model for PNFs, even more so taking into account
that currently there is no tumoroid model generated
directly from primary PNF cells. An in vitro 3D PNF modelnd FiPS) and PNF-derived iPSCs differentiated to NCs (passage 5)
stain cell nuclei. Scale bar, 50 mm.
X10, AP2), and SC (S100B) markers, in pluripotent cells (PSCs), PSCs
sed as the mean normalized relative expression (NRE) ± SEM from
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Figure 4. Schwann Cells Differentiation of iPSC-Derived NCs
(A) Top: schematic representation of the protocol used for differentiating NCs to Schwann cells (SCs). NCs were seeded on poly-L-lysine and
laminin-coated plates and cultured in SC differentiation medium (see Supplemental Experimental Procedures). After 7, 14, and 30 days, SC
differentiation was monitored by qRT-PCR and immunocytochemistry analysis. Representative bright-field images during the differen-
tiation process from a control cell line are shown. Scale bars, 50 mm. Bottom: diagram showing the expression of markers associated with
the NC-SC lineage. The colored horizontal bars represent the temporal window during differentiation when the corresponding marker is
expressed in vivo, according to the literature (Jessen and Mirsky, 2005). SCP, Schwann cell precursor; iSC, immature Schwann cells (iSCs).
(B and C) Immunocytochemical analysis for S100b and p75 at different stages of SC differentiation (7, 14, and 30 days) in control NF1(+/+)
FiPS (B) and 3PNFiPS(/) cells (C). DAPI was used to stain cell nuclei. Scale bars, 50 mm.
(D and E) qRT-PCR in control NF1(+/+) FiPS (D) and NF1(/) iPSCs (E) at five different time points during differentiation: pluripotent
stage (PSC), neural crest stage (NC) and at 7, 14, or 30 days of SC differentiation. For NF1(/) iPSC graphs (E): light bar represents SC
differentiation for 3PNF and dark bar for 5PNF. As control cells for marker expression, primary SC cultures (gray bars) from 3PNF (light gray)
and 5PNF (dark gray) were used. Values are expressed as the mean NRE ± SEM from three independent differentiation experiments.
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will facilitate the testing of therapeutic agents in a PNF-
resembling environment before jumping to an in vivo
model, although further development will be necessary.
In the field of NF1 research, there is still an open debate
regarding the cell of origin of neurofibromas (Buchstaller
et al., 2012). PNFs are thought to be congenital but the
identity and biological capacity of the cell type that re-
ceives the inactivation ofNF1 is still not completely under-
stood. Essential information has been obtained from the
different genetically modified mouse models that develop
PNFs in which NF1 ablation is driven by Cre recombinase
expressed under promoters active along the NC-SC differ-
entiation axis. The ability to differentiate PNF-derived
iPSCs toward NCs and SCs could complement the informa-
tion coming from genetically modified mice.
In summary, we have generated NF1(/) iPSCs directly
from PNFs. They represent an iPSC-based non-perishable
cell model system for a benign tumor. NF1(/) iPSCs
contain the same naturally occurring mutations as their
primary counterparts and preserve their proliferative prop-
erties when differentiated fromNCs toward SCs. SCs differ-
entiated from PNF-derived iPSCs have a high tendency to
form spheres. This cell-based model system constitutes a
great tool to investigate the PNF cell of origin, the genetic
and epigenetic changes required for progression toward
MPNSTs and finally, a model to test new therapeutic strate-
gies before pre-clinical in vivo models.EXPERIMENTAL PROCEDURES
Patients, Plexiform Neurofibromas, and Tumor
Processing
Tumor samples were kindly provided by NF1 patients after giving
written informed consent for iPSC generation and genomic anal-
ysis studies. The study was approved by our Institutional Review
Board and local ethical commitees. The patients were diagnosed
according to standard diagnostic criteria (DeBella et al., 2000). Tu-
mor specimens were obtained after surgery of five PNFs from five
independent patients (two males, three females; ages 8–66 years).
Immediately after excision, tumor samples were placed in DMEMFigure 5. NF1(/) Differentiating SCs Exhibited a Continuous H
(A) Representative bright-field images after 20 days of differentiati
5PNFiPS(/) cells exhibited a high cell density and the formation
(B) Macroscopic detail of sphere formation in 3PNiPS(/) and 5PN
(C) Proliferation capacity of differentiating SCs. Representative imm
ferentiation. DAPI was used to stain cell nuclei. Scale bars, 50 mm.
(D) Quantification of Ki-67-positive cells (percentage over total DAP
differentiation experiments). At least 300 nuclei were counted per tim
test).
(E and F) Myelination capacity of control NF1(+/+) FiPS (E) and NF1
entiated SCs (at 7 days) with rat DRG neurons for 30 days. SC myelinat
MPZ. Scale bars, 50 mm.
(G) PNF-derived SC immunostained with TUJ1, S100b, and MPZ. Scale
422 Stem Cell Reports j Vol. 12 j 411–426 j February 12, 2019medium (Gibco) containing 10% FBS (Gibco) + 13 Glx (Gibco) +
13 normocin antibiotic cocktail (InvivoGene), and shipped at
room temperature to our laboratory. Tumors were processed as fol-
lows: surrounding fat tissue and skin were removed and tumors
were cut into 1-mm pieces and cryopreserved in 10% DMSO
(Sigma) + 90% FBS until used.PNF-Derived SCs and Fibroblasts Cultures
PNF-derived SCs and fibroblasts were isolated as described previ-
ously (Serra et al., 2000). In brief, PNF pieces that were preserved
in liquid nitrogen were thawed and digested with 160 U/mL colla-
genase type 1 and 0.8 U/mL dispase (Worthington, Lakewood, NJ)
for 16 h at 37C. Dissociated cells were washed and seeded onto
0.1 mg/mL poly-L-lysine (Sigma) and 4 mg/mL laminin (Gibco)-
coated dishes in Schwann cell medium (SCM) and maintained at
37C under a 10% CO2 atmosphere. SCM is DMEM (Gibco) with
10% FBS, 500 U/mL penicillin/500 mg/mL streptomycin (Gibco),
0.5 mM 3-iso-butyl-1-methilxantine (Sigma), 2.5 mg/mL insulin
(Sigma), 10 nM heregulin-b1 (PeproTech), and 0.5 mM forskolin
(Sigma). One day after plating, culture medium was replaced by
SCM without forskolin for an additional 2–3 days. This process
was repeated in cycles and cells were passaged as needed with
trypsin 0.05% (Gibco). SC purity was assessed by performing
S100b staining as described previously (Serra et al., 2000). To isolate
fibroblasts, dissociated cells were plated in DMEM 10% FBS media
and passaged when necessary.Reprogramming of SCs, Fibroblasts, and Digested
Tumors
Between 1 3 104 and 2 3 104 cells were reprogrammed through
the retroviral delivery of human cDNA coding for OCT4, SOX2,
KLF4, and cMYC transcription factors as described previously
(Raya et al., 2009). For non-integrative reprogramming, a Cyto-
tune-iPS 2.0 Sendai Reprogramming Kit (Thermo Fisher Scientific)
was used according to themanufacturer’s protocol. Approximately
3 or 4 weeks after transduction, colonies displaying embryonic
stem cell-like morphology and behavior were selected for further
characterization and genotyping. iPSC established lines were
grown on dishes coated with growth factor-reduced Matrigel (BD
Biosciences) in mTESR1 medium (STEMCELL Technologies).
See Supplemental Information for a detailed description of iPSC
characterization.igh Proliferation Rate and a Lack of Myelinating Capacity
on from NC to SC for different NF1 genotypes. 3PNFiPS(/) and
of 3D spheres. Scale bars, 50 mm.
FiPS(/) cells during SC differentiation.
unofluorescence images of Ki-67 (green) at 7 and 30 days of dif-
I-positive nuclei) expressed as the mean ± SE (n = 3 independent
e point and sample. *p < 0.05, **p < 0.01, ***p < 0.001 (unpaired t
(/) iPSCs (F). Myelination was assessed by co-culturing differ-
ion capacity was measured by immunostaining for TUJ1, S100b, and
bars, 50 mm.
Figure 6. Sphere-Forming SCs from NF1(/) iPSCs Recapitulate the Expression Pattern of their PNF-Derived Primary SC Coun-
terparts
(A) Representative immunofluorescence images showing expression of S100b, p75, SOX10, GAP43, and PLP, in 5PNF primary SCs (PNF SC)
compared with sphere-forming 5PNFiPS(/) differentiating SCs, at 30 days of differentiation. Scale bars, 100 mm.
(B) Schematic representation of the generated PNF model.Differentiation toward NCs and SCs
Neural crest differentiation was performed as described byMenen-
dez et al. (2013) with some modifications. In brief, 9 3 104 cells/
cm2 were plated onto Matrigel-coated plates in mTESR medium.
The following day, the medium was replaced with hESC mainte-
nance medium: DMEM:F12 (Gibco) 1:1; 5 mg/mL BSA (Sigma);
500 U/mL penicillin/500 mg/mL streptomycin (Gibco); 2 mMGlu-
taMAX (Gibco); 13 MEM non-essential amino acids (Gibco); 13
trace elements A; 13 trace elements B; 13 trace elements C (Corn-
ing); 2-mercaptoethanol (Gibco); 10 mg/mL transferrin (Sigma);
50 mg/mL sodium L-ascorbate (Sigma); 10 ng/mL heregulin-b1
(PeproTech); 10 ng/mL activin A (PeproTech); 200 mg/mL LONG
R3 IGFR (PeproTech); 8 ng/mL basic fibroblast growth factor 2
(PeproTech). Next day, the medium was replaced with neural crest
induction/differentiation medium: hESCmediumwithout activin
and supplemented with 2 mM CHIR9902 (STEMCELL Technolo-
gies) and 20 mM SB432542 (STEMCELL Technologies), and was
replaced every day. NCs were maintained in this medium and split
with Accutase (Thermo Fischer Scientific) when necessary.
For SC differentiation NCs were plated onto 0.1 mg/mL poly-L-
lysine (Sigma) and 4 mg/mL laminin (Gibco)-coated plates
and cultured in SC differentiation medium: DMEM:F12 (3:1);500 U/ml penicillin/500 mg/mL streptomycin antibiotics (Gibco);
5 mM forskolin (Sigma); 50 ng/mL heregulin-b1; 2% N2 supple-
ment (Gibco); 1% FBS (Gibco). The medium was replaced twice
a week.
Additional Experimental Procedures
Additional experimental procedures can be found in Supplemental
Information.REPOSITORIES
The iPSC lines generated have been banked banked and are
currently distributed by the Spanish National Stem Cell
Bank-Institute of Health Carlos III in compliance with the
informed consent signed by the patient (see Table 1).
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